Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Select Advanced Solid Tumors 1Pain 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Humoral Hypercalcemia Of Malignancy 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × Antibodies, Monoclonal × Clear all
NCT02855086 2020-03-31

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Stanford University

Phase 1/2 Terminated
3 enrolled 7 charts
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡